Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates

被引:98
作者
Smith, TAG
Idamakanti, N
Marshall-Neff, J
Rollence, ML
Wright, P
Kaloss, M
King, L
Mech, C
Dinges, L
Iverson, WO
Sherer, AD
Markovits, JE
Lyons, RM
Kaleko, M
Stevenson, SC
机构
[1] Genet Therapy Inc, Gaithersburg, MD 20878 USA
[2] Novartis Pharmaceut Inc, E Hanover, NJ 07936 USA
[3] Adv Vis Therapies Inc, Rockville, MD 20854 USA
关键词
D O I
10.1089/104303403322542248
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Adenovirus serotype 5 (Ad5)-based vectors can bind at least three separate cell surface receptors for efficient cell entry: the coxsackie-adenovirus receptor (CAR), alphaupsilon integrins, and heparan sulfate glycosaminoglycans (HSG). To address the role of each receptor involved in adenoviral cell entry, we mutated critical amino acids in fiber or penton to inhibit receptor interaction. A series of five adenoviral vectors was prepared and the biodistribution of each was previously characterized in mice. To evaluate possible species differences in Ad vector tropism, we characterized the effects of each detargeting mutation in non-human primates after systemic delivery to confirm our conclusions made in mice. In non-human primates, CAR was found to have minimal effects on vector delivery to all organs examined including liver and spleen. Cell-surface ay integrins played a significant role in delivery of vector to the spleen, lung and kidney. The fiber shaft mutation S*, which presumably inhibits HSG binding, was found to significantly decrease delivery to all organs examined. The ability to detarget the liver corresponded with decreased elevations in liver serum enzymes (aspartate transferase [AST] and alanine transferase [ALT]) 24 hr after vector administration and also in serum interleukin (IL)-6 levels 6 hr after vector administration. The biodistribution data generated in cynomolgus monkeys correspond with those data derived from mice, demonstrating that CAR binding is not the major determinant of viral tropism in vivo. Vectors containing the fiber shaft modification may provide for a detargeted adenoviral vector on which to introduce new tropisms for the development of targeted, systemically deliverable adenoviral vectors for human clinical application.
引用
收藏
页码:1595 / 1604
页数:10
相关论文
共 35 条
  • [1] Blood clearance rates of adenovirus type 5 in mice
    Alemany, R
    Suzuki, K
    Curiel, DT
    [J]. JOURNAL OF GENERAL VIROLOGY, 2000, 81 : 2605 - 2609
  • [2] CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors
    Alemany, R
    Curiel, DT
    [J]. GENE THERAPY, 2001, 8 (17) : 1347 - 1353
  • [3] Evaluation of the duration of human factor VIII expression in nonhuman primates after systemic delivery of an adenoviral vector
    Andrews, JL
    Shirley, PS
    Iverson, WO
    Sherer, AD
    Markovits, JE
    King, L
    Lyons, RM
    Kaleko, M
    Connelly, S
    [J]. HUMAN GENE THERAPY, 2002, 13 (11) : 1331 - 1336
  • [4] Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5
    Bergelson, JM
    Cunningham, JA
    Droguett, G
    KurtJones, EA
    Krithivas, A
    Hong, JS
    Horwitz, MS
    Crowell, RL
    Finberg, RW
    [J]. SCIENCE, 1997, 275 (5304) : 1320 - 1323
  • [5] Adenoviral vector-mediated expression of physiologic levels of human factor VIII in nonhuman primates
    Brann, T
    Kayda, D
    Lyons, RM
    Shirley, P
    Roy, S
    Kaleko, M
    Smith, T
    [J]. HUMAN GENE THERAPY, 1999, 10 (18) : 2999 - 3011
  • [6] Immune responses to adenovirus and adeno-associated virus in humans
    Chirmule, N
    Propert, KJ
    Magosin, SA
    Qian, Y
    Qian, R
    Wilson, JM
    [J]. GENE THERAPY, 1999, 6 (09) : 1574 - 1583
  • [7] The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction
    Cohen, CJ
    Shieh, JTC
    Pickles, RJ
    Okegawa, T
    Hsieh, JT
    Bergelson, JM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (26) : 15191 - 15196
  • [8] Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy
    Connelly, S
    Andrews, JL
    Gallo, AM
    Kayda, DB
    Qian, JH
    Hoyer, L
    Kadan, MJ
    Gorziglia, MI
    Trapnell, BC
    McClelland, A
    Kaleko, M
    [J]. BLOOD, 1998, 91 (09) : 3273 - 3281
  • [9] Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions
    Dechecchi, MC
    Tamanini, A
    Bonizzato, A
    Cabrini, G
    [J]. VIROLOGY, 2000, 268 (02) : 382 - 390
  • [10] Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5
    Dechecchi, MC
    Melotti, P
    Bonizzato, A
    Santacatterina, M
    Chilosi, M
    Cabrini, G
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (18) : 8772 - 8780